Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial

BACKGROUND: Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purpose of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ming-Huan, Liu, Zhen-Jing, Hu, Qiong-Yue, Yang, Jia-Yu, Jin, Ying, Zhu, Na, Huang, Ying, Shi, Dian-Hong, Liu, Min-Jia, Tan, Hong-Yang, Zhao, Lei, Lv, Qin-Yu, Yi, Zheng-Hui, Wu, Feng-Chun, Li, Ze-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578180/
https://www.ncbi.nlm.nih.gov/pubmed/36253804
http://dx.doi.org/10.1186/s40779-022-00420-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578180/
https://www.ncbi.nlm.nih.gov/pubmed/36253804
http://dx.doi.org/10.1186/s40779-022-00420-0

Ejemplares similares